Disease activity CD | Disease activity UC | |||||||
---|---|---|---|---|---|---|---|---|
CD | UC | Remission | Mild | Moderate | Remission | Mild | Moderate | |
Subjects, n (%) | 168 (51) | 161 (49) | 123 (73) | 27 (16) | 18 (11) | 108 (67) | 38 (24) | 15 (9) |
Gender, n (%) | ||||||||
Female | 117 (70) | 97 (60) | 84 (68) | 17 (63) | 16 (89) | 60 (56) | 27 (71) | 10 (67) |
Age (years) | 47 ± 16* | 51 ± 15* | 48 ± 16 | 46 ± 17 | 47 ± 14 | 50 ± 14 | 54 ± 16 | 45 ± 16 |
Age at diagnosis (years) | 32 ± 15* | 36 ± 15* | 33 ± 16 | 30 ± 14 | 33 ± 9 | 35 ± 14 | 41 ± 17 | 32 ± 15 |
BMI (kg/m2) | 24.8 ± 4.7 | 24.9 ± 3.8 | 24.8 ± 4.4 | 24.9 ± 5.1 | 25.0 ± 6.6 | 24.7 ± 3.6 | 25.4 ± 3.9 | 24.8 ± 4.9 |
Smoking, n (%) | ||||||||
Never | 123 (73) | 124 (77) | 97 (79)a | 17 (63)a, b | 9 (50)b | 80 (74) | 31 (82) | 13 (87) |
Current | 16 (10) | 7 (4) | 8 (7)a | 6 (22)b | 2 (11)a, b | 5 (5) | 1 (3) | 1 (7) |
Former | 29 (17) | 30 (19) | 18 (15)a | 4 (15)a, b | 7 (39)b | 23 (21) | 6 (16) | 1 (7) |
Education levelc, n (%) | ||||||||
Low | 37 (22) | 34 (21) | 25 (20) | 7 (26) | 5 (28) | 21 (19) | 10 (26) | 3 (20) |
Middle | 52 (31) | 48 (30) | 38 (31) | 5 (19) | 9 (50) | 33 (31) | 8 (21) | 7 (47) |
High | 79 (47) | 79 (49) | 60 (49) | 15 (56) | 4 (22) | 54 (50) | 20 (53) | 5 (33) |
Medication use, n (%) | ||||||||
Mesalazines | 28 (17)** | 97 (60)** | 21 (17) | 4 (15) | 3 (17) | 65 (60) | 21 (55) | 11 (73) |
Corticosteroids | 22 (13) | 24 (15) | 13 (11) | 6 (22) | 3 (17) | 9 (8)a | 10 (26)b | 5 (33)b |
Immunosuppressants | 70 (42)** | 33 (21)** | 52 (42) | 11 (41) | 7 (39) | 20 (19) | 9 (24) | 4 (27) |
Biologicals | 58 (35)** | 27 (17)** | 36 (29) | 12 (44) | 10 (56) | 11 (10)a | 9 (24)a, b | 7 (47)b |
Other | 24 (14)* | 11 (7)* | 14 (11) | 6 (22) | 4 (22) | 4 (4)a | 4 (11)a, b | 3 (20)b |
No medication use | 34 (20) | 30 (19) | 29 (24) | 4 (15) | 1 (6) | 24 (22) | 6 (16) | 0 (0) |
Flare-ups in past year, n (%) | ||||||||
None | 92 (55)* | 61 (38)* | 80 (65)a | 7 (26)b | 5 (28)b | 50 (46)a | 10 (26)a, b | 1 (7)b |
1–2 flare-ups | 55 (33)* | 70 (44)* | 35 (29) | 14 (52) | 6 (33) | 45 (42) | 20 (53) | 5 (33) |
3–4 flare-ups | 8 (5)* | 19 (12)* | 2 (2)a | 4 (15)b | 2 (11)a, b | 8 (7)a | 4 (11)a | 7 (47)b |
More than 4 flare-ups | 13 (7) | 11 (7) | 6 (5)a | 2 (7)a, b | 5 (28)b | 5 (5) | 4 (11) | 2 (13) |
Supplement use, n (%) | 74 (44) | 68 (42) | 54 (44) | 11 (41) | 9 (50) | 39 (36) | 21 (55) | 8 (53) |
Surgery, n (%) | 57 (34)** | 13 (8)** | 40 (33) | 8 (30) | 9 (50) | 6 (6) | 6 (16) | 1 (7) |
Intolerances/allergies, n (%) | 62 (37) | 44 (27) | 40 (33) | 13 (48) | 9 (50) | 23 (21)a | 16 (42)b | 5 (33)a, b |